keyword
MENU ▼
Read by QxMD icon Read
search

Lymphome

keyword
https://www.readbyqxmd.com/read/28601705/abvd-or-beacoppbaseline-along-with-involved-field-radiotherapy-in-early-stage-hodgkin-lymphoma-with-risk-factors-results-of-the-european-organisation-for-research-and-treatment-of-cancer-eortc-groupe-d-%C3%A3-tude-des-lymphomes-de-l-adulte-gela-h9-u-intergroup-randomised
#1
Christophe Fermé, José Thomas, Pauline Brice, Olivier Casasnovas, Andrej Vranovsky, Serge Bologna, Pieternella J Lugtenburg, Réda Bouabdallah, Patrice Carde, Catherine Sebban, Houchingue Eghbali, Gilles Salles, Gustaaf W van Imhoff, Antoine Thyss, Evert M Noordijk, Oumédaly Reman, Marnix L M Lybeert, Maud Janvier, Michele Spina, Bruno Audhuy, John M M Raemaekers, Richard Delarue, Bruno Anglaret, Okke de Weerdt, Zora Marjanovic, Robbert J H A Tersteeg, Daphne de Jong, Josette Brière, Michel Henry-Amar
PURPOSE: For early-stage Hodgkin lymphoma (HL), optimal chemotherapy regimen and the number of cycles to be delivered remain to settle down. The H9-U trial compared three modalities of chemotherapy followed by involved-field radiotherapy (IFRT) in patients with stage I-II HL and risk factors (NCT00005584). PATIENTS AND METHODS: Patients aged 15-70 years with untreated supradiaphragmatic HL with at least one risk factor (age ≥ 50, involvement of 4-5 nodal areas, mediastinum/thoracic ratio ≥ 0...
June 7, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28476440/efficacy-and-safety-of-subcutaneous-rituximab-versus-intravenous-rituximab-for-first-line-treatment-of-follicular-lymphoma-sabrina-a-randomised-open-label-phase-3-trial
#2
Andrew Davies, Francesco Merli, Biljana Mihaljević, Santiago Mercadal, Noppadol Siritanaratkul, Philippe Solal-Céligny, Axel Boehnke, Claude Berge, Magali Genevray, Artem Zharkov, Mark Dixon, Michael Brewster, Martin Barrett, David MacDonald
BACKGROUND: Intravenous rituximab is the standard of care in B-cell non-Hodgkin lymphoma, and is administered over 1·5-6 h. A subcutaneous formulation could reduce patients' treatment burden and improve resource utilisation in health care. We aimed to show the pharmacokinetic non-inferiority of subcutaneous rituximab to intravenous rituximab in follicular lymphoma and to provide efficacy and safety data. METHODS: SABRINA is a two-stage, randomised, open-label phase 3 study at 113 centres in 30 countries...
June 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28378140/management-of-non-hodgkin-lymphoma-icmr-consensus-document
#3
Nirav Thacker, Sameer Bakhshi, Girish Chinnaswamy, Tushar Vora, Maya Prasad, Deepak Bansal, Sandeep Agarwala, Gauri Kapoor, Venkatraman Radhakrishnan, Siddharth Laskar, Tanvir Kaur, G K Rath, Rupinder Singh Dhaliwal, Brijesh Arora
Hitherto poor outcomes, paucity of data and heterogeneity in International approach to Pediatric NHL (Non-Hodgkin Lymphoma) prompted the need for guidelines for Indian population with vast variability in access, affordability and infrastructure across the country. These guidelines are based on consensus among the experts and best available evidence applicable to Indian setting. Evaluation of NHL should consist of easily doable and rapid tissue diagnosis (biopsy or flow cytometry of peripheral blood/malignant effusions), St Jude/IPNHLSS (International Pediatric Non-Hodgkin Lymphoma Staging System) and risk grouping with CSF (Cerebro-spinal fluid), bone marrow, whole body imaging [CECT (Contrast enhanced computerized tomography) ± MRI (Magnetic resonance imaging)] and blood investigations for LDH (Lactate dehydrogenase), TLS (Tumor lysis syndrome) and organ functions...
May 2017: Indian Journal of Pediatrics
https://www.readbyqxmd.com/read/28252849/intral%C3%A3-sionale-therapie-niedrig-maligner-prim%C3%A3-r-kutaner-b-zell-lymphome-mit-anti-cd20-antik%C3%A3-rper-nebenwirkungen-korrelieren-mit-gutem-klinischen-ansprechen
#4
Franziska C Eberle, Julia Holstein, Alexander Scheu, Falko Fend, Amir S Yazdi
HINTERGRUND UND ZIEL: Die intraläsionale Gabe von Anti-CD20-Antikörpern (Rituximab) wurde als effektive Therapieoption für Patienten mit niedrig malignen primär kutanen B-Zell-Lymphomen beschrieben. Bis heute wurden allerdings keine Parameter identifiziert, welche reproduzierbar ein gutes klinisches Ansprechen dieser Therapie vorhersagen. Ziel dieser Studie ist, sowohl das klinische Ansprechen und die unerwünschten Nebenwirkungen als auch die Patientenwahrnehmung hinsichtlich intraläsionaler Injektionen von anti-CD20-Antikörpern zur Behandlung indolenter primär kutaner B-Zell-Lymphome im Vergleich mit anderen Therapien zu evaluieren...
March 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28252845/die-diagnostik-und-therapie-kutaner-lymphome-erfordert-spezielle-klinische-und-dermatohistologische-kenntnisse
#5
EDITORIAL
Claus-Detlev Klemke
No abstract text is available yet for this article.
March 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/27992139/b-zell-lymphome-der-haut-pathogenese-diagnostik-und-therapie
#6
Jan P Nicolay, Marion Wobser
Primär kutane B-Zell-Lymphome (PCBCL) beschreiben reifzellige lymphoproliferative Erkrankungen der B-Zell-Reihe, die primär die Haut betreffen. Die Biologie und der klinische Verlauf der einzelnen PCBCL-Subtypen variieren untereinander stark und unterscheiden sich grundsätzlich von primär nodalen und systemischen B-Zell-Lymphomen. Primär kutane Marginalzonenlymphome (PCMZL) und primäre kutane follikuläre Keimzentrumslymphome (PCFCL) werden auf Grund ihres unkomplizierten Verlaufs und ihrer exzellenten Prognose zu den indolenten PCBCL gezählt...
December 2016: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/27509410/prim%C3%A3-r-kutane-cd30-lymphoproliferative-erkrankungen
#7
Iris Wieser, Michael T Tetzlaff, Carlos A Torres Cabala, Madeleine Duvic
Primär kutane CD30(+) lymphoproliferative Erkrankungen zählen zu der zweit häufigsten Gruppe der kutanen T-Zell-Lymphome (CTCL) und umfassen die Krankheitsbilder der lymphomatoiden Papulose (LyP) und des primär kutanen anaplastischen großzelligen Lymphoms (cALCL). Beide Erkrankungen haben klinische, histopathologische und molekulare Gemeinsamkeiten und repräsentieren ein Spektrum von kutanen CD30(+) lymphoproliferativen Erkrankungen. Man kann LyP vom cALCL anhand des Zusammenspiels von klinischen und histopathologischen Befunden unterscheiden...
August 2016: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/27175513/role-of-follow-up-endoscopic-examination-in-treatment-response-assessment-for-patients-with-gastric-diffuse-large-b-cell-lymphoma
#8
Seung Bae Yoon, In Seok Lee, Ha Ni Lee, Eunyoung Kim, Woohyeon Kim, Han Hee Lee, Bo-In Lee, Myung-Gyu Choi, Seung Eun Jung, Byung Ock Choi, Gyeong Sin Park, Seok-Goo Cho
OBJECTIVE: According to lymphoma guidelines, gastric diffuse large B cell lymphoma (DLBCL) patients should undergo regular computed tomography (CT) and/or positron emission tomography (PET) examinations to assess treatment response. Endoscopic examinations are not indicated in the guidelines. The aim of this study was to investigate the utility of endoscopic examinations during and after treatment for DLBCL. METHODS: We reviewed the patients diagnosed with gastric DLBCL at Seoul St...
September 2016: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/27080498/rituximab-and-dose-dense-chemotherapy-for-adults-with-burkitt-s-lymphoma-a-randomised-controlled-open-label-phase-3-trial
#9
RANDOMIZED CONTROLLED TRIAL
Vincent Ribrag, Serge Koscielny, Jacques Bosq, Thibaut Leguay, Olivier Casasnovas, Luc-Mathieu Fornecker, Christian Recher, Hervé Ghesquieres, Franck Morschhauser, Stéphane Girault, Steven Le Gouill, Mario Ojeda-Uribe, Clara Mariette, Jerome Cornillon, Guillaume Cartron, Veronique Verge, Catherine Chassagne-Clément, Hervé Dombret, Bertrand Coiffier, Thierry Lamy, Hervé Tilly, Gilles Salles
BACKGROUND: Short intensive chemotherapy is the standard of care for adult patients with Burkitt's leukaemia or lymphoma. Findings from single-arm studies suggest that addition of rituximab to these regimens could improve patient outcomes. Our objective was to test this possibility in a randomised trial. METHODS: In this randomised, controlled, open-label, phase 3 trial, we recruited patients older than 18 years with untreated HIV-negative Burkitt's lymphoma (including Burkitt's leukaemia) from 45 haematological centres in France...
June 11, 2016: Lancet
https://www.readbyqxmd.com/read/26979715/-progress-due-to-networking-structures-challenges-for-the-competence-network-malignant-lymphomas-in-the-era-of-precision-medicine
#10
Silke Hellmich, Natalie Schreiber, Birgit Fath, Michael Hallek
The Competence Network Malignant Lymphomas (KML), founded in 1999 at the initiative of the Federal Ministry of Education and Research (BMBF), brings together interdisciplinary medical and scientific expertise in research on malignant lymphomas. The network helps to release synergies in evidence-based clinical research and contributes to the accelerated transfer of advances in knowledge gained from therapeutic studies for the health care of lymphoma patients. During the regular BMBF funding period (1999-2009) individual sub-projects were hived off, such as the Cochrane Haematological Malignancies Group (CHMG) or the Scientific Institute of Haematologists and Oncologists in Private Practice (WINHO GmbH)...
April 2016: Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
https://www.readbyqxmd.com/read/26972188/s%C3%A3-zary-syndrom-von-ungel%C3%A3-sten-fragen-zu-neuen-therapieans%C3%A3-tzen
#11
REVIEW
Jan P Nicolay, Moritz Felcht, Kai Schledzewski, Sergij Goerdt, Cyrill Géraud
Das Sézary-Syndrom, die leukämische Variante des kutanen T-Zell-Lymphoms, stellt immer noch eine Erkrankung mit vielen ungelösten Fragen sowie einer sehr ungünstigen Prognose dar. In jüngeren Forschungsarbeiten wurde jedoch eine Vielzahl an fehlregulierten molekularen Signalwegen identifiziert, die zur malignen Transformation und Therapieresistenz von Sézary-Zellen (SC) beitragen. Im Hinblick auf die T-Zell-Entwicklung repräsentieren SC entweder naive T-Zellen, T-Effektor-Gedächtniszellen oder zentrale T-Gedächtniszellen...
March 2016: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/26686259/cardiovascular-disease-after-treatment-for-hodgkin-s-lymphoma-an-analysis-of-nine-collaborative-eortc-lysa-trials
#12
Maja V Maraldo, Francesco Giusti, Ivan R Vogelius, Michael Lundemann, Marleen A E van der Kaaij, Safaa Ramadan, Bart Meulemans, Michel Henry-Amar, Berthe M P Aleman, John Raemaekers, Paul Meijnders, Elisabeth C Moser, Hanneke C Kluin-Nelemans, Pierre Feugier, Olivier Casasnovas, Catherine Fortpied, Lena Specht
BACKGROUND: Cardiovascular disease after treatment is an important concern in cancer survivors. However, knowledge of cardiotoxicity is limited by the retrospective nature of data, which often does not contain details of treatment exposure. To facilitate individual risk counselling of patients, we aimed to quantify the effect of anthracyclines, vinca-alkaloids, and radiotherapy on the risk of cardiovascular disease in patients treated for Hodgkin's lymphoma. METHODS: In 2009-10, a Life Situation Questionnaire (LSQ) was distributed to patients by mail to assess late-onset effects of Hodgkin's lymphoma treatment in patients who were included in nine successive European Organisation for Research and Treatment of Cancer (EORTC) and the Groupe d'Etude des Lymphomes de l'Adulte (GELA, now renamed LYSA) randomised trials between 1964 and 2004...
November 2015: Lancet Haematology
https://www.readbyqxmd.com/read/26655425/bendamustine-plus-rituximab-versus-fludarabine-plus-rituximab-for-patients-with-relapsed-indolent-and-mantle-cell-lymphomas-a-multicentre-randomised-open-label-non-inferiority-phase-3-trial
#13
RANDOMIZED CONTROLLED TRIAL
Mathias Rummel, Ulrich Kaiser, Christina Balser, Martina Stauch, Wolfram Brugger, Manfred Welslau, Norbert Niederle, Christoph Losem, Hans-Peter Boeck, Eckhart Weidmann, Ulrich von Gruenhagen, Lothar Mueller, Michael Sandherr, Lars Hahn, Julia Vereshchagina, Frank Kauff, Wolfgang Blau, Axel Hinke, Juergen Barth
BACKGROUND: Fludarabine-based chemoimmunotherapy with rituximab is frequently used in patients with indolent and mantle-cell lymphomas who relapse after alkylating chemotherapy. We aimed to compare the efficacy and safety of rituximab with bendamustine or fludarabine in patients with relapsed, indolent, non-Hodgkin lymphoma and mantle-cell lymphoma. METHODS: For this randomised, non-inferiority, open-label, phase 3 trial, we recruited patients from 55 centres in Germany, who were subsequently randomised centrally according to prespecified randomisation lists with permuted blocks of randomly variable block size to rituximab (375 mg/m(2), day 1) plus either bendamustine (90 mg/m(2), days 1 and 2) or fludarabine (25 mg/m(2), days 1-3) every 28 days for a maximum of six 28-day cycles...
January 2016: Lancet Oncology
https://www.readbyqxmd.com/read/26395311/exclusive-moderate-dose-radiotherapy-in-gastric-marginal-zone-b-cell-malt-lymphoma-results-of-a-prospective-study-with-a-long-term-follow-up
#14
Agnès Ruskoné-Fourmestraux, Tamara Matysiak-Budnik, Bettina Fabiani, Pascale Cervera, Hedia Brixi, Karine Le Malicot, Isabelle Nion-Larmurier, Jean-Fançois Fléjou, Christophe Hennequin, Laurent Quéro
BACKGROUND: In gastric MALT lymphomas persisting after Helicobacter pylori (H. pylori) eradication, a treatment by moderate-dose radiotherapy (RT) has been proposed but its efficacy has not been confirmed in large prospective series with long term endoscopic follow-up. METHOD: Patients with localised gastric MALT lymphoma persisting after H. pylori eradication were offered moderate-dose RT (30Gy, 2Gy/fraction) and followed with annual endoscopies. All biopsies before and after RT were reviewed by a committee of pathologists...
October 2015: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/26185174/concomitant-systemic-and-central-nervous-system-non-hodgkin-lymphoma-the-role-of-consolidation-in-terms-of-high-dose-therapy-and-autologous-stem-cell-transplantation-a-60-case-retrospective-study-from-lysa-and-the-loc-network
#15
MULTICENTER STUDY
Gandhi Damaj, Sarah Ivanoff, Diane Coso, Loïc Ysaebert, Sylvain Choquet, Caroline Houillier, Anne Parcelier, Wajed Abarah, Zora Marjanovic, Rémy Gressin, Reda Garidi, Momar Diouf, Anne-Claire Gac, Jehan Dupuis, Xavier Troussard, Franck Morschhauseur, Hervé Ghesquières, Carole Soussain
The purpose of our study is to determine the outcome of patients with systemic non-Hodgkin lymphoma presenting with neurologic localization at diagnosis, as well as the impact of consolidation in terms of high-dose therapy followed by autologous stem cell transplantation. Newly diagnosed non-Hodgkin lymphoma patients with concomitant systemic and neurological involvement at diagnosis were included in this study. Sixty patients (37 males; 25 females) were included. Median age was 61 years (23-85 years). Histological subtype was mainly diffuse large B-cell lymphoma (n = 54; 90%)...
September 2015: Haematologica
https://www.readbyqxmd.com/read/26112525/-curing-burkitt-lymphomas-from-france-to-africa
#16
C Patte, F Traore, M El Kababri, C Bouda, G Leverger, M-A Raquin, M Harif
No abstract text is available yet for this article.
May 2015: Archives de Pédiatrie: Organe Officiel de la Sociéte Française de Pédiatrie
https://www.readbyqxmd.com/read/25858645/impact-of-persistent-minimal-residual-disease-post-consolidation-therapy-in-children-and-adolescents-with-advanced-burkitt-leukaemia-a-children-s-oncology-group-pilot-study-report
#17
MULTICENTER STUDY
Bruce Shiramizu, Stanton Goldman, Lynette Smith, Melissa Agsalda-Garcia, Paul Galardy, Sherrie L Perkins, J Kimble Frazer, Warren Sanger, James R Anderson, Thomas G Gross, Howard Weinstein, Lauren Harrison, Matthew J Barth, Lara Mussolin, Mitchell S Cairo
Patient-specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French-British-American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real-time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71% (5/7) were MRD-positive at EOI and EOC, respectively, with no disease recurrences...
August 2015: British Journal of Haematology
https://www.readbyqxmd.com/read/25852262/helicobacter-pylori-eradication-in-gastric-diffuse-large-b-cell-lymphoma
#18
REVIEW
Semra Paydas
Diffuse large B cell lymphoma (DLBCL) of the stomach is a heterogenous disease. There are tumors without histological evidence of mucosa-associated lymphoid tissue (MALT) lymphoma, which are classified as pure or de novo DLBCL and those with evidence of MALT, which are classified as DLBCL (MALT). The association between Helicobacter pylori (H. pylori) and gastric MALT lymphoma and remission with H. pylori eradication was shown in the 1990s. In recent years, scientists from Taiwan and others have shown that high-grade gastric lymphomas may be dependent on H...
April 7, 2015: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/25819238/elektrochemotherapie-bei-fortgeschrittenen-hauttumoren-und-hautmetastasen-eine-retrospektive-multizentrische-auswertung
#19
Alexander Kreuter, Tina van Eijk, Percy Lehmann, Matthias Fischer, Thomas Horn, Chalid Assaf, Gaston Schley, Rudolf Herbst, Ivonne Kellner, Christiane Weisbrich, Julia Hyun, Ulrike Wieland, Max Schlaak, Albert Rübben, Kerstin Lommel
HINTERGRUND: Nach Ausschöpfung von klassischen Behandlungsverfahren wie Chemo- und Strahlentherapie existieren bei ausgedehnten Hauttumoren oder Hautmetastasen nur wenige Optionen einer lokalen Tumorkontrolle. In diesen Fällen kann die Elektrochemotherapie als Therapiealternative in Erwägung gezogen werden. PATIENTEN UND METHODIK: Im Rahmen einer retrospektiven Studie wurden klinische Charakteristika, Ansprechen und Bedingungen des Ansprechens sowie Nebenwirkungen von 56 Patienten untersucht, die an sechs deutschen Hautkliniken behandelt wurden...
April 2015: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/25819233/neue-dermatologische-systemtherapien-bei-kinderwunsch-schwangerschaft-und-stillzeit
#20
Sonja Grunewald, Alexander Jank
Mit Einführung zahlreicher neuer, überwiegend biologischer Systemtherapien in der Dermatologie stellt sich im klinischen Alltag regelmäßig die Frage, inwieweit eine Anwendung bei Kinderwunsch oder in Schwangerschaft und Stillzeit möglich ist und welche Risiken ggf. damit verbunden sind. Seriöse Informationen liefern neben Fachinformation und Roter Liste Datenbanken wie die des Pharmakovigilanz- und Beratungszentrums für Embryonaltoxikologie der Charité Berlin (https://www.embryotox.de) oder eine Literaturrecherche (z...
April 2015: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
keyword
keyword
8529
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"